It’s that time of the year again.  As part of the annual pilgrimage, acolytes of the healthcare investment community are about to descend upon the Union Square area of San Francisco. As part of the ritual of the 34th Annual

The past five years have been the greatest bull run in the history of the biotech industry. Stock market outperformance, significant fundraising levels both private and public, more IPOs in this window than ever before, and huge volumes of M&A.

We’re excited to announce two new collaborations today from our neuroscience portfolio – Quartet with Merck (here) and Rodin with Biogen (here) – to advance their programs into early clinical development.  These are both young companies that we helped create

This blog was written by Mike Gilman, CEO of Padlock Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. I stumbled into a bit of a mess a few weeks ago. It was with the best of intentions, of course.

As 2015 comes to a conclusion, it’s a good time reflect on the year’s progress – celebrating the wins, thinking through the losses, and learning from both. One specific reflection of late regards this blog: I’ve looked back at the

This year I celebrated my 10-year work anniversary with Atlas.  Hard to believe how fast a decade flies by, and this milestone triggered some reflections on how times have changed in biotech and the early stage venture business. As we

This blog was written by Ron Renaud, CEO of RaNA Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. It is that time of the year again when we start to get ready for the New Year.  It is

Over the past seven years, Celgene has emerged as one of the most active and creative deal-makers in the biopharma industry. The Boston Consulting Group’s Biopharma Partnering Survey and Benchmarking analysis examines BD activity and perceptions across the industry, and

This blog was written by Rosana Kapeller, CSO of Nimbus Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. It is the holiday season and as we gorge on delicious and heavy food, and inevitably resolve to eat less

This blog was written by Ankit Mahadevia, CEO at Spero Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. In my experience, looking to the outside world for new pipeline ideas isn’t just the realm of larger companies.   The

The exciting renaissance in cell and gene therapy over the past five years has yielded some of the most innovative medical advances in the industry’s pipeline today.  There are now multiple stories of patients getting “cured” of rare diseases, responding

This blog was written by Kevin Pojasek, CEO at Quartet and Atlas EIR, as part of the “From the Trenches” feature of LifeSciVC. Therapeutic areas and modalities regularly fall in and out fashion usually when promising scientific approaches run aground in